2025 Q3 -tulosraportti
64 päivää sittenTarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
0,556VWAP
Alin
0,499VaihtoMäärä
2,7 5 263 881
VWAP
Ylin
0,556Alin
0,499VaihtoMäärä
2,7 5 263 881
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 30.10.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 30.5.2025 | |
| 2024 Q4 -tulosraportti | 27.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
25.12.2025 · Muokattu25.12.2025 · MuokattuFirst of all, I'd like to say that I'm not an expert. These are; A: Mixed facts, notes, searches, comments, reports I've taken from various places - B: Google AI. I've used A and B in combination trying to confirm each part just to be as sure as possible, along with a ton of repeated and follow-up questions. I've spent countless hours on this, but do not take it as pure fact, do your own research and make your own assumptions. I've also written this in english if any translation errors occurs. With that said… ________________ 1. During Q3 PSTV reported the following numbers: Research and Development: -$2,44M General and Administrative: -$3,44M Total Operating Expenses: -$5,88M Which means a monthly burn rate of -$1,96M Whether or not the financial support award from NCI/NIH is included and settled in the financial report from PSTV I am not sure, but I left out the other two from CPRIT and DoD just for good measure. Operating expenses increased from Q2 ($-2,93M) to Q3 (-$5,88M), most likely due to the recruiting, the new laboratory and the administrative work for expanding CNSide. If the expenses will increase in Q4 we will have to see, but I'd say it's likely. With current cash and current burn rate, my calculations say we have about 4,5 months from EOY, roughly speaking. ________________ 2. So, let's talk about CNSide, PSTV and BIOCQ: PSTV sent out a PR saying: "More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020". This was during the period of time Biocept(BIOCQ) owned CNSide, and they actually released it commercially in April 2021, and had it up and running until October 2023 when they went bankrupt. So again, for good measure, let's say 10 000 tests as some test probably were done before the commercial release. That means about 10 000 tests during a 30 months time period, which means 333 tests/month. However, BIOCQ did not have the same national coverage, both insurances and state licenses. PSTV is way ahead already with 48 licensed states and two major insurance companies (UHC and Humana). Even though we're licensed in 48 states out of 50, there's still administrative work to be done to actually get the tests rolling, so far we're only active in Texas. I'd assume the highest priority are California, Florida and Maryland as these are market giants - we're still missing two other giants however; New York and Pennsylvania, where we have not received the corresponding licenses to operate. The official preliminary price from CMS/Medicare of each test is set to roughly $2 500, which is within range of some earlier analysts price estimates. The average margin of each test should be around 50%, less tests = worse margins - more tests = better margin, but let's set it at 50%. ________________ 3. Just give me the damn calculations: So let's assume the price is $2 500, with a margin of 50%, that equals $1 250 in profit for each test. With my calculations, BIOCQ had an average of 333 tests/month, which is a monthly profit of $0,42M. With a monthly burn rate of -$1,96M that is not enough, not even with possible grant payments included, but it's close. This is where it hopefully is different with PSTV. As mentioned, we're in a better position than BIOCQ were, but we're not there exactly yet. It's hard to say how many tests we've done so far, but only with Texas operating, it might not be that many. Yet. To somewhat cover the Q3 burn rate, my calculations say that we'll need about 550 tests/month, without grant payments that is. ________________ 4. So what's next: This is why I feel the progress with expanding outside Texas is absolute key. If we can complete either California, Florida or Maryland, or two, or all three, we're in a much better position. Also, the Medicare enrollment, which is underway, is also a huge factor. It will most likely bring the majority of the tests, as well as set the price standard to $2 500, and when CMS/Medicare sets a price, the lot of the insurance companies tend to follow their lead when it comes to pricing, as they otherwise may not pay as much. And why is all this important, you might ask? We want to be able to stand on our own legs, even though a continued agreement with LPC might save us from bankruptcy, it will dilute the stock and keep the stock price down. As as you all know, we're on a compliance deadline with NASDAQ. We'll have to see when they release the financial report for Q4, but until then, a lot can happen. Also, mainly speaking just for the stock price movements up until then, advancements in the ReSPECT Clinical Trials could move the price by itself - but for the economic future of PSTV, CNSide is their foundation, it's what makes them different from other Biotech companies.
27.12.2025 · Muokattu27.12.2025 · Muokattuhttps://stockscan.io/stocks/PSTV/forecast what might be base of stories on this page? The same pages are forecast -78 % to Siemens Energy AG in January 2026? Good that i did not bought Siemens.- ·24.12.2025Has anyone here done some calculations on how many CNSide tests we might need to counteract future ATMs with, for example, LPC, to avoid dilution and actually cover most of OPEX? I've been doing some calculations myself, but it would be interesting if someone else has too!
·24.12.2025can you share your calculations·25.12.2025Absolutely, though I don't think I'll make it today, but maybe tomorrow. Would love to hear your thoughts too! - 23.12.202523.12.2025Tää on kyllä aika paska·24.12.2025Good question 😊 The reason I have chosen to be heavily invested in PSTV right now is a deliberate strategy. I have limited capital to work with, and for me, it makes more sense to concentrate it in one case I have followed closely, rather than spreading it thinly across "safer" companies where the potential and progress are slower. I am aware of the risk and that this can take time and also that it can fail. But this is capital I can afford to tie up and potentially lose. If they succeed, it can give me a very good starting point going forward than a very defensive portfolio. So it's not random, but a conscious choice based on risk, time horizon and potential 👍
22.12.202522.12.2025
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
64 päivää sittenUutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 25.12.2025 · Muokattu25.12.2025 · MuokattuFirst of all, I'd like to say that I'm not an expert. These are; A: Mixed facts, notes, searches, comments, reports I've taken from various places - B: Google AI. I've used A and B in combination trying to confirm each part just to be as sure as possible, along with a ton of repeated and follow-up questions. I've spent countless hours on this, but do not take it as pure fact, do your own research and make your own assumptions. I've also written this in english if any translation errors occurs. With that said… ________________ 1. During Q3 PSTV reported the following numbers: Research and Development: -$2,44M General and Administrative: -$3,44M Total Operating Expenses: -$5,88M Which means a monthly burn rate of -$1,96M Whether or not the financial support award from NCI/NIH is included and settled in the financial report from PSTV I am not sure, but I left out the other two from CPRIT and DoD just for good measure. Operating expenses increased from Q2 ($-2,93M) to Q3 (-$5,88M), most likely due to the recruiting, the new laboratory and the administrative work for expanding CNSide. If the expenses will increase in Q4 we will have to see, but I'd say it's likely. With current cash and current burn rate, my calculations say we have about 4,5 months from EOY, roughly speaking. ________________ 2. So, let's talk about CNSide, PSTV and BIOCQ: PSTV sent out a PR saying: "More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020". This was during the period of time Biocept(BIOCQ) owned CNSide, and they actually released it commercially in April 2021, and had it up and running until October 2023 when they went bankrupt. So again, for good measure, let's say 10 000 tests as some test probably were done before the commercial release. That means about 10 000 tests during a 30 months time period, which means 333 tests/month. However, BIOCQ did not have the same national coverage, both insurances and state licenses. PSTV is way ahead already with 48 licensed states and two major insurance companies (UHC and Humana). Even though we're licensed in 48 states out of 50, there's still administrative work to be done to actually get the tests rolling, so far we're only active in Texas. I'd assume the highest priority are California, Florida and Maryland as these are market giants - we're still missing two other giants however; New York and Pennsylvania, where we have not received the corresponding licenses to operate. The official preliminary price from CMS/Medicare of each test is set to roughly $2 500, which is within range of some earlier analysts price estimates. The average margin of each test should be around 50%, less tests = worse margins - more tests = better margin, but let's set it at 50%. ________________ 3. Just give me the damn calculations: So let's assume the price is $2 500, with a margin of 50%, that equals $1 250 in profit for each test. With my calculations, BIOCQ had an average of 333 tests/month, which is a monthly profit of $0,42M. With a monthly burn rate of -$1,96M that is not enough, not even with possible grant payments included, but it's close. This is where it hopefully is different with PSTV. As mentioned, we're in a better position than BIOCQ were, but we're not there exactly yet. It's hard to say how many tests we've done so far, but only with Texas operating, it might not be that many. Yet. To somewhat cover the Q3 burn rate, my calculations say that we'll need about 550 tests/month, without grant payments that is. ________________ 4. So what's next: This is why I feel the progress with expanding outside Texas is absolute key. If we can complete either California, Florida or Maryland, or two, or all three, we're in a much better position. Also, the Medicare enrollment, which is underway, is also a huge factor. It will most likely bring the majority of the tests, as well as set the price standard to $2 500, and when CMS/Medicare sets a price, the lot of the insurance companies tend to follow their lead when it comes to pricing, as they otherwise may not pay as much. And why is all this important, you might ask? We want to be able to stand on our own legs, even though a continued agreement with LPC might save us from bankruptcy, it will dilute the stock and keep the stock price down. As as you all know, we're on a compliance deadline with NASDAQ. We'll have to see when they release the financial report for Q4, but until then, a lot can happen. Also, mainly speaking just for the stock price movements up until then, advancements in the ReSPECT Clinical Trials could move the price by itself - but for the economic future of PSTV, CNSide is their foundation, it's what makes them different from other Biotech companies.27.12.2025 · Muokattu27.12.2025 · Muokattuhttps://stockscan.io/stocks/PSTV/forecast what might be base of stories on this page? The same pages are forecast -78 % to Siemens Energy AG in January 2026? Good that i did not bought Siemens.
- ·24.12.2025Has anyone here done some calculations on how many CNSide tests we might need to counteract future ATMs with, for example, LPC, to avoid dilution and actually cover most of OPEX? I've been doing some calculations myself, but it would be interesting if someone else has too!·24.12.2025can you share your calculations·25.12.2025Absolutely, though I don't think I'll make it today, but maybe tomorrow. Would love to hear your thoughts too!
- 23.12.202523.12.2025Tää on kyllä aika paska·24.12.2025Good question 😊 The reason I have chosen to be heavily invested in PSTV right now is a deliberate strategy. I have limited capital to work with, and for me, it makes more sense to concentrate it in one case I have followed closely, rather than spreading it thinly across "safer" companies where the potential and progress are slower. I am aware of the risk and that this can take time and also that it can fail. But this is capital I can afford to tie up and potentially lose. If they succeed, it can give me a very good starting point going forward than a very defensive portfolio. So it's not random, but a conscious choice based on risk, time horizon and potential 👍
- 22.12.202522.12.2025
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
0,556VWAP
Alin
0,499VaihtoMäärä
2,7 5 263 881
VWAP
Ylin
0,556Alin
0,499VaihtoMäärä
2,7 5 263 881
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 30.10.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 30.5.2025 | |
| 2024 Q4 -tulosraportti | 27.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
64 päivää sittenUutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 30.10.2025 | |
| 2025 Q2 -tulosraportti | 14.8.2025 | |
| 2025 Q1 -tulosraportti | 30.5.2025 | |
| 2024 Q4 -tulosraportti | 27.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 25.12.2025 · Muokattu25.12.2025 · MuokattuFirst of all, I'd like to say that I'm not an expert. These are; A: Mixed facts, notes, searches, comments, reports I've taken from various places - B: Google AI. I've used A and B in combination trying to confirm each part just to be as sure as possible, along with a ton of repeated and follow-up questions. I've spent countless hours on this, but do not take it as pure fact, do your own research and make your own assumptions. I've also written this in english if any translation errors occurs. With that said… ________________ 1. During Q3 PSTV reported the following numbers: Research and Development: -$2,44M General and Administrative: -$3,44M Total Operating Expenses: -$5,88M Which means a monthly burn rate of -$1,96M Whether or not the financial support award from NCI/NIH is included and settled in the financial report from PSTV I am not sure, but I left out the other two from CPRIT and DoD just for good measure. Operating expenses increased from Q2 ($-2,93M) to Q3 (-$5,88M), most likely due to the recruiting, the new laboratory and the administrative work for expanding CNSide. If the expenses will increase in Q4 we will have to see, but I'd say it's likely. With current cash and current burn rate, my calculations say we have about 4,5 months from EOY, roughly speaking. ________________ 2. So, let's talk about CNSide, PSTV and BIOCQ: PSTV sent out a PR saying: "More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020". This was during the period of time Biocept(BIOCQ) owned CNSide, and they actually released it commercially in April 2021, and had it up and running until October 2023 when they went bankrupt. So again, for good measure, let's say 10 000 tests as some test probably were done before the commercial release. That means about 10 000 tests during a 30 months time period, which means 333 tests/month. However, BIOCQ did not have the same national coverage, both insurances and state licenses. PSTV is way ahead already with 48 licensed states and two major insurance companies (UHC and Humana). Even though we're licensed in 48 states out of 50, there's still administrative work to be done to actually get the tests rolling, so far we're only active in Texas. I'd assume the highest priority are California, Florida and Maryland as these are market giants - we're still missing two other giants however; New York and Pennsylvania, where we have not received the corresponding licenses to operate. The official preliminary price from CMS/Medicare of each test is set to roughly $2 500, which is within range of some earlier analysts price estimates. The average margin of each test should be around 50%, less tests = worse margins - more tests = better margin, but let's set it at 50%. ________________ 3. Just give me the damn calculations: So let's assume the price is $2 500, with a margin of 50%, that equals $1 250 in profit for each test. With my calculations, BIOCQ had an average of 333 tests/month, which is a monthly profit of $0,42M. With a monthly burn rate of -$1,96M that is not enough, not even with possible grant payments included, but it's close. This is where it hopefully is different with PSTV. As mentioned, we're in a better position than BIOCQ were, but we're not there exactly yet. It's hard to say how many tests we've done so far, but only with Texas operating, it might not be that many. Yet. To somewhat cover the Q3 burn rate, my calculations say that we'll need about 550 tests/month, without grant payments that is. ________________ 4. So what's next: This is why I feel the progress with expanding outside Texas is absolute key. If we can complete either California, Florida or Maryland, or two, or all three, we're in a much better position. Also, the Medicare enrollment, which is underway, is also a huge factor. It will most likely bring the majority of the tests, as well as set the price standard to $2 500, and when CMS/Medicare sets a price, the lot of the insurance companies tend to follow their lead when it comes to pricing, as they otherwise may not pay as much. And why is all this important, you might ask? We want to be able to stand on our own legs, even though a continued agreement with LPC might save us from bankruptcy, it will dilute the stock and keep the stock price down. As as you all know, we're on a compliance deadline with NASDAQ. We'll have to see when they release the financial report for Q4, but until then, a lot can happen. Also, mainly speaking just for the stock price movements up until then, advancements in the ReSPECT Clinical Trials could move the price by itself - but for the economic future of PSTV, CNSide is their foundation, it's what makes them different from other Biotech companies.27.12.2025 · Muokattu27.12.2025 · Muokattuhttps://stockscan.io/stocks/PSTV/forecast what might be base of stories on this page? The same pages are forecast -78 % to Siemens Energy AG in January 2026? Good that i did not bought Siemens.
- ·24.12.2025Has anyone here done some calculations on how many CNSide tests we might need to counteract future ATMs with, for example, LPC, to avoid dilution and actually cover most of OPEX? I've been doing some calculations myself, but it would be interesting if someone else has too!·24.12.2025can you share your calculations·25.12.2025Absolutely, though I don't think I'll make it today, but maybe tomorrow. Would love to hear your thoughts too!
- 23.12.202523.12.2025Tää on kyllä aika paska·24.12.2025Good question 😊 The reason I have chosen to be heavily invested in PSTV right now is a deliberate strategy. I have limited capital to work with, and for me, it makes more sense to concentrate it in one case I have followed closely, rather than spreading it thinly across "safer" companies where the potential and progress are slower. I am aware of the risk and that this can take time and also that it can fail. But this is capital I can afford to tie up and potentially lose. If they succeed, it can give me a very good starting point going forward than a very defensive portfolio. So it's not random, but a conscious choice based on risk, time horizon and potential 👍
- 22.12.202522.12.2025
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
0,556VWAP
Alin
0,499VaihtoMäärä
2,7 5 263 881
VWAP
Ylin
0,556Alin
0,499VaihtoMäärä
2,7 5 263 881
Välittäjätilasto
Dataa ei löytynyt